Literature DB >> 18337375

Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.

D Neil Wedlock1, Michel Denis, Gavin F Painter, Gary D Ainge, H Martin Vordermeier, R Glyn Hewinson, Bryce M Buddle.   

Abstract

Current efforts are aimed at optimizing the protective efficacy of Mycobacterium bovis BCG by the use of vaccine combinations. We have recently demonstrated that the protection afforded by BCG alone is enhanced by vaccinating cattle with a combination of vaccines comprising BCG and a protein tuberculosis vaccine, namely, culture filtrate proteins (CFPs) from M. bovis plus an adjuvant. In the current study, three different adjuvant systems were compared. The CFP was formulated with a depot adjuvant, dimethyldioctadecyl ammonium bromide (DDA), together with one of three different immunostimulants: monophosphoryl lipid A (MPL), a synthetic mycobacterial phosphatidylinositol mannoside-2 (PIM2), and a synthetic lipopeptide (Pam3Cys-SKKKK [Pam(3)CSK(4)]). Groups of cattle (n = 10/group) were vaccinated with BCG-CFP-DDA-PIM2, BCG-CFP-DDA-MPL, or BCG-CFP-DDA-Pam(3)CSK(4). Two additional groups (n = 10) were vaccinated with BCG alone or BCG-adjuvant (DDA-MPL), and a control group was left unvaccinated. Protection was assessed by challenging the cattle intratracheally with M. bovis. Groups of cattle vaccinated with BCG-CFP-DDA-PIM2, BCG-CFP-DDA-MPL, BCG-CFP-DDA-Pam(3)CSK(4), and BCG alone showed significant reductions in three, three, five, and three pathological and microbiological disease parameters, respectively, compared to the results for the nonvaccinated group. Vaccination with the combination of BCG and the DDA-MPL adjuvant alone abrogated the protection conferred by BCG alone. The profiling of cytokine gene expression following vaccination, prior to challenge, did not illuminate significant differences which could explain the latter result. Vaccination of cattle with a combination of BCG and protein tuberculosis vaccine enhances protection against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337375      PMCID: PMC2394838          DOI: 10.1128/CVI.00034-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  51 in total

1.  Immunostimulation by bacterial components: I. Activation Of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4.

Authors:  U vd Esche; M Ayoub; S D Pfannes; M R Müller; M Huber; K H Wiesmüller; T Loop; M Humar; K F Fischbach; M Strünkelnberg; P Hoffmann; W G Bessler; K Mittenbühler
Journal:  Int J Immunopharmacol       Date:  2000-12

2.  Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis.

Authors:  Bryce M Buddle; Barry J Wards; Frank E Aldwell; Desmond M Collins; Geoffrey W de Lisle
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  Different Toll-like receptor agonists induce distinct macrophage responses.

Authors:  B W Jones; T K Means; K A Heldwein; M A Keen; P J Hill; J T Belisle; M J Fenton
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

4.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  The 19-kD antigen and protective immunity in a murine model of tuberculosis.

Authors:  V V Yeremeev; I V Lyadova; B V Nikonenko; A S Apt; C Abou-Zeid; J Inwald; D B Young
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 6.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001

7.  Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response.

Authors:  Martine Gilleron; Valérie F J Quesniaux; Germain Puzo
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

8.  A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis.

Authors:  Margot A Skinner; Bryce M Buddle; D Neil Wedlock; Denise Keen; Geoffrey W de Lisle; Ricardo E Tascon; Jose Candido Ferraz; Douglas B Lowrie; Paul J Cockle; H Martin Vordermeier; R Glyn Hewinson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection.

Authors:  Avi-Hai Hovav; Jacob Mullerad; Liuba Davidovitch; Yolanta Fishman; Fabiana Bigi; Angel Cataldi; Herve Bercovier
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Innate gene repression associated with Mycobacterium bovis infection in cattle: toward a gene signature of disease.

Authors:  Kieran G Meade; Eamonn Gormley; Mairéad B Doyle; Tara Fitzsimons; Cliona O'Farrelly; Eamon Costello; Joseph Keane; Yingdong Zhao; David E MacHugh
Journal:  BMC Genomics       Date:  2007-10-31       Impact factor: 3.969

View more
  17 in total

1.  Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Authors:  Natalie A Parlane; Katrin Grage; Jun Mifune; Randall J Basaraba; D Neil Wedlock; Bernd H A Rehm; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

Review 2.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  Ac2PIM-responsive miR-150 and miR-143 target receptor-interacting protein kinase 2 and transforming growth factor beta-activated kinase 1 to suppress NOD2-induced immunomodulators.

Authors:  Praveen Prakhar; Sahana Holla; Devram Sampat Ghorpade; Martine Gilleron; Germain Puzo; Vibha Udupa; Kithiganahalli Narayanaswamy Balaji
Journal:  J Biol Chem       Date:  2015-09-21       Impact factor: 5.157

4.  Highly purified mycobacterial phosphatidylinositol mannosides drive cell-mediated responses and activate NKT cells in cattle.

Authors:  Chris Pirson; Regina Engel; Gareth J Jones; Thomas Holder; Otto Holst; H Martin Vordermeier
Journal:  Clin Vaccine Immunol       Date:  2014-12-10

5.  Mycobacterium bovis DNA detection in colostrum as a potential indicator of vaccination effectiveness against bovine tuberculosis.

Authors:  Sara E Herrera-Rodríguez; María Alejandra Gordiano-Hidalgo; Gonzálo López-Rincón; Luis Bojorquez-Narváez; Francisco Javier Padilla-Ramírez; Ana Laura Pereira-Suárez; Mario Alberto Flores-Valdez; Ciro Estrada-Chávez
Journal:  Clin Vaccine Immunol       Date:  2013-02-20

6.  Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection.

Authors:  Scott T Nolan; Gyanu Lamichhane
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 7.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

8.  Identification of novel Mycobacterium bovis antigens by dissection of crude protein fractions.

Authors:  V Meikle; A Alito; A S Llera; A Gioffré; A Peralta; B M Buddle; A Cataldi
Journal:  Clin Vaccine Immunol       Date:  2009-07-29

Review 9.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

10.  Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge.

Authors:  Caroline Rizzi; María Verónica Bianco; Federico Carlos Blanco; Marcelo Soria; María José Gravisaco; Valeria Montenegro; Lucas Vagnoni; Bryce Buddle; Sergio Garbaccio; Fernando Delgado; Karen Silva Leal; Angel Adrián Cataldi; Odir Antônio Dellagostin; Fabiana Bigi
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.